Sheaff Brock Investment Advisors LLC Purchases 1,150 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Sheaff Brock Investment Advisors LLC raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 12.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 10,454 shares of the biotechnology company’s stock after buying an additional 1,150 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Exelixis were worth $248,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Alaska Permanent Fund Corp lifted its stake in shares of Exelixis by 1.2% in the 1st quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company’s stock valued at $1,263,000 after purchasing an additional 617 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 728 shares during the period. Quadrant Capital Group LLC raised its stake in Exelixis by 10.8% during the 4th quarter. Quadrant Capital Group LLC now owns 7,709 shares of the biotechnology company’s stock worth $185,000 after buying an additional 750 shares during the period. Banque Cantonale Vaudoise raised its stake in Exelixis by 11.5% during the 1st quarter. Banque Cantonale Vaudoise now owns 7,555 shares of the biotechnology company’s stock worth $179,000 after buying an additional 781 shares during the period. Finally, Jennison Associates LLC raised its stake in Exelixis by 0.5% during the 4th quarter. Jennison Associates LLC now owns 164,200 shares of the biotechnology company’s stock worth $3,939,000 after buying an additional 815 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

Exelixis stock traded up $0.43 during midday trading on Friday, reaching $23.39. 1,693,637 shares of the company’s stock were exchanged, compared to its average volume of 1,242,114. Exelixis, Inc. has a 52 week low of $18.64 and a 52 week high of $24.34. The firm has a market cap of $7.09 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 0.57 and a beta of 0.54. The stock’s 50-day simple moving average is $21.93 and its 200 day simple moving average is $22.18.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business had revenue of $425.23 million for the quarter, compared to the consensus estimate of $461.04 million. During the same quarter in the previous year, the business posted $0.12 EPS. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. Research analysts forecast that Exelixis, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

EXEL has been the topic of several research analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research note on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. Barclays cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a report on Thursday, April 11th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Finally, Stephens initiated coverage on Exelixis in a report on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 target price for the company. Seven analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.13.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 8,287 shares of Exelixis stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the transaction, the director now owns 349,499 shares in the company, valued at $7,688,978. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Exelixis news, Director Jack L. Wyszomierski sold 10,923 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $21.37, for a total transaction of $233,424.51. Following the completion of the sale, the director now directly owns 338,948 shares in the company, valued at $7,243,318.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack L. Wyszomierski sold 8,287 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the sale, the director now owns 349,499 shares of the company’s stock, valued at $7,688,978. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,896 shares of company stock worth $660,677. Company insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.